Participant List
Meeting of Invited Experts

Workshop on Quality Risk Management: Making Clinical Trials Fit for Purpose
A Clinical Trials Transformation Initiative (CTTI)-Sponsored Meeting

August 23 - 24, 2011
Hyatt Regency Bethesda
One Bethesda Metro Center, Bethesda, MD 20814

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brenda Aker</td>
<td>Biosense Webster</td>
</tr>
<tr>
<td>John Alexander</td>
<td>Duke University</td>
</tr>
<tr>
<td>Carlos Ammann</td>
<td>Booz &amp; Company GmbH</td>
</tr>
<tr>
<td>Patrick Archdeacon</td>
<td>Food and Drug Administration, CDER</td>
</tr>
<tr>
<td>Leslie Ball</td>
<td>Food and Drug Administration, CDER</td>
</tr>
<tr>
<td>Robert Ball</td>
<td>Food and Drug Administration, CBER</td>
</tr>
<tr>
<td>Mark Behm</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Lisa Berdan</td>
<td>Duke Clinical Research Institute</td>
</tr>
<tr>
<td>Pierre Henri Bertoye</td>
<td>AFSSAPS (French Health Products Safety Agency)</td>
</tr>
<tr>
<td>Kelly Blackburn</td>
<td>Vertex Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Jean Bolte</td>
<td>Clinical Trials Transformation Initiative</td>
</tr>
<tr>
<td>Oana Brosteanu</td>
<td>Universitaet Leipzig</td>
</tr>
<tr>
<td>Sara Calvert</td>
<td>Duke Clinical Research Institute</td>
</tr>
<tr>
<td>Chrsisy Cochran</td>
<td>Food and Drug Administration, CDRH</td>
</tr>
<tr>
<td>Rory Collins</td>
<td>University of Oxford</td>
</tr>
<tr>
<td>Karena Cooper</td>
<td>Food and Drug Administration, CDER</td>
</tr>
<tr>
<td>Steve Cummings</td>
<td>San Francisco Coordinating Center</td>
</tr>
<tr>
<td>Jacques Demotes</td>
<td>European Clinical Research Infrastructures Network (ECRIN)</td>
</tr>
<tr>
<td>Regina Freunscht</td>
<td>Accovion GmbH</td>
</tr>
<tr>
<td>Larry Friedman</td>
<td>Independent Consultant</td>
</tr>
<tr>
<td>Ken Getz</td>
<td>Tufts University</td>
</tr>
<tr>
<td>Cheryl Grandinetti</td>
<td>Food and Drug Administration, CDER</td>
</tr>
<tr>
<td>Melina Griffis</td>
<td>Food and Drug Administration, CDER</td>
</tr>
</tbody>
</table>
Manish Gupta
St. Jude Medical

Felix Gyi
Chesapeake Research Review

Jonathan Helfgott
Food and Drug Administration, CDER

Ed Helton
National Cancer Institute, NIH

Adrian Hernandez
Duke Clinical Research Institute

Greg Hockel
Pharmanet

Patricia Holobaugh
Food and Drug Administration, CBER

Grant Huang
US Department of Veterans Affairs

Cheri Janning
Clinical Trials Transformation Initiative

Elizabeth Joseph
Boehringer Ingelheim Pharmaceuticals, Inc.

Jeff Kasher
Eli Lilly and Company

Cynthia Kleppinger
Food and Drug Administration, CDER

Judith Kramer
Clinical Trials Transformation Initiative

Andy Lawton
Boehringer Ingelheim Limited

Andy Lee
Genzyme

Barbara Leishman
Roche

Joanne Less
FDA, Office of Good Clinical Practice

Lisa Horne Lucero
Eli Lilly and Company

Debra Madden
Breast Cancer Patient Representative/ Research Advocate

Diane Maloney
Food and Drug Administration, CBER

Michael Marcarelli
Food and Drug Administration, CDRH

Amanda McMillan
Duke Clinical Research Institute

Ann Meeker O’Connell
Food and Drug Administration, CDER

Kathleen Meely
Medicines and Healthcare Products Regulatory Agency (MHRA)

Jerry Menikoff
Office for Human Research Protections (OHRP)

Thomas Moreno
Food and Drug Administration, CBER

Bob Moroz
Merck

Briggs Morrison
Pfizer, Inc.

Jean Mulinde
Food and Drug Administration, CDER

Mike Neidl
Genzyme

Dave Nickerson
Pfizer, Inc.

Paul Okwesili
Food and Drug Administration, CDER

Tomoko Osawa
Pharmaceuticals and Medical Devices Agency (PMDA)

Jacqueline O’Shaughnessy
Food and Drug Administration, CDER

Doug Peddicord
Association of Clinical Research Organizations (ACRO)

Ray Policare
Amgen